Expanding Possibilities

July 1, 2003

San Francisco - The expanding indications for the topical immune response modulator imiquimod (Aldara) may soon include treatment of superficial basal cell carcinoma (BCC), Mark Naylor, M.D., said at the annual meeting of the American Academy of Dermatology.

Related Content:

News